Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) CFO Sells $933,553.87 in Stock

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) CFO Charles N. York II sold 52,183 shares of Day One Biopharmaceuticals stock in a transaction that occurred on Wednesday, May 1st. The shares were sold at an average price of $17.89, for a total transaction of $933,553.87. Following the sale, the chief financial officer now owns 225,571 shares of the company’s stock, valued at $4,035,465.19. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Day One Biopharmaceuticals Trading Down 2.3 %

Day One Biopharmaceuticals stock opened at $17.17 on Monday. The firm has a market cap of $1.50 billion, a P/E ratio of -7.21 and a beta of -1.44. Day One Biopharmaceuticals, Inc. has a 1-year low of $9.67 and a 1-year high of $18.07. The firm has a 50-day moving average of $15.45 and a 200-day moving average of $14.07.

Day One Biopharmaceuticals (NASDAQ:DAWN) last released its quarterly earnings data on Monday, February 26th. The company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.57) by ($0.07). Research analysts forecast that Day One Biopharmaceuticals, Inc. will post -2.67 earnings per share for the current fiscal year.

Institutional Trading of Day One Biopharmaceuticals

Several large investors have recently added to or reduced their stakes in the stock. Quest Partners LLC purchased a new stake in shares of Day One Biopharmaceuticals in the 4th quarter worth about $29,000. China Universal Asset Management Co. Ltd. boosted its position in Day One Biopharmaceuticals by 130.9% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 2,226 shares of the company’s stock valued at $27,000 after acquiring an additional 1,262 shares in the last quarter. Quintet Private Bank Europe S.A. grew its holdings in shares of Day One Biopharmaceuticals by 43.2% during the 4th quarter. Quintet Private Bank Europe S.A. now owns 3,313 shares of the company’s stock worth $48,000 after acquiring an additional 1,000 shares during the period. Amalgamated Bank raised its position in shares of Day One Biopharmaceuticals by 35.7% in the 3rd quarter. Amalgamated Bank now owns 8,628 shares of the company’s stock worth $106,000 after acquiring an additional 2,268 shares in the last quarter. Finally, Exchange Traded Concepts LLC lifted its stake in shares of Day One Biopharmaceuticals by 34.0% in the 4th quarter. Exchange Traded Concepts LLC now owns 10,072 shares of the company’s stock valued at $147,000 after purchasing an additional 2,554 shares during the period. Institutional investors own 87.95% of the company’s stock.

Wall Street Analysts Forecast Growth

DAWN has been the subject of a number of research analyst reports. Piper Sandler reaffirmed an “overweight” rating and set a $40.00 price objective on shares of Day One Biopharmaceuticals in a report on Tuesday, March 26th. Needham & Company LLC upped their price objective on shares of Day One Biopharmaceuticals from $30.00 to $33.00 and gave the company a “buy” rating in a research note on Wednesday, April 24th. HC Wainwright reiterated a “buy” rating and issued a $50.00 target price on shares of Day One Biopharmaceuticals in a research report on Wednesday, April 24th. JPMorgan Chase & Co. upped their price target on shares of Day One Biopharmaceuticals from $32.00 to $36.00 and gave the company an “overweight” rating in a research report on Monday, April 22nd. Finally, Wedbush reiterated an “outperform” rating and issued a $33.00 price objective on shares of Day One Biopharmaceuticals in a report on Wednesday, April 24th. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Day One Biopharmaceuticals has an average rating of “Moderate Buy” and an average price target of $39.33.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.